Horio Yoshitsugu, Tachibana Hiroyuki, Shimizu Junichi, Hosoda Waki, Fujiwara Yutaka
Department of Outpatient Services Aichi Cancer Center Hospital Nagoya Japan.
Department of Thoracic Oncology Aichi Cancer Center Hospital Nagoya Japan.
Respirol Case Rep. 2022 Mar 9;10(4):e0919. doi: 10.1002/rcr2.919. eCollection 2022 Apr.
Treatment of extensive-stage (ES) small cell lung cancer (SCLC) is a challenge with poor local control and dismal overall survival. Although single extrathoracic metastasis was defined as M1b according to the eighth edition of the tumour-node-metastasis (TNM) classification of lung cancer, M1b includes involvement of a single intrathoracic nonregional lymph node (LN) such as pericardial, internal mammary or paravertebral LNs. Here, we report a successful treated case of a 50-year-old female with ES-SCLC with right pericardial LN involvement, cT1cN3M1b (LYM). She initially received two cycles of induction chemotherapy consisting of cis-Diamminedichloroplatinum/cisplatin (CDDP) and etoposide and achieved a very good partial response. She then received curative chemoradiotherapy with intensity-modulated techniques (45 Gy in 30 fractions BID), followed by an additional cycle of chemotherapy. She is free of recurrence for more than 2.5 years.
广泛期（ES）小细胞肺癌（SCLC）的治疗是一项挑战，局部控制不佳且总体生存率惨淡。根据肺癌的第八版肿瘤-淋巴结-转移（TNM）分类，虽然单个胸外转移被定义为M1b，但M1b包括单个胸内非区域淋巴结（LN）受累，如心包、乳内或椎旁淋巴结。在此，我们报告一例成功治疗的50岁女性ES-SCLC病例，伴有右心包淋巴结受累，cT1cN3M1b（LYM）。她最初接受了两个周期的诱导化疗，由顺二氯二氨铂/顺铂（CDDP）和依托泊苷组成，并取得了非常好的部分缓解。然后她接受了调强技术的根治性放化疗（45 Gy，分30次，每日两次），随后又进行了一个周期的化疗。她已无复发超过2.5年。
